Genetic diagnosis of haemophilia and other inherited bleeding disorders
- PMID: 16684001
- DOI: 10.1111/j.1365-2516.2006.01263.x
Genetic diagnosis of haemophilia and other inherited bleeding disorders
Abstract
Inherited deficiencies of plasma proteins involved in blood coagulation generally lead to lifelong bleeding disorders, whose severity is inversely proportional to the degree of factor deficiency. Haemophilia A and B, inherited as X-linked recessive traits, are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of blood coagulation factor VIII (FVIII) and factor IX (FIX). Together with von Willebrand's disease, a defect of primary haemostasis, these X-linked disorders include 95% to 97% of all the inherited deficiencies of coagulation factors. The remaining defects, generally transmitted as autosomal recessive traits, are rare with prevalence of the presumably homozygous forms in the general population of 1:500,000 for FVII deficiency and 1 in 2 million for prothrombin (FII) and factor XIII (FXIII) deficiency. Molecular characterization, carrier detection and prenatal diagnosis remain the key steps for the prevention of the birth of children affected by coagulation disorders in developing countries, where patients with these deficiencies rarely live beyond childhood and where management is still largely inadequate. These characterizations are possible by direct or indirect genetic analysis of genes involved in these diseases, and the choice of the strategy depends on the effective available budget and facilities to achieve a large benefit. In countries with more advanced molecular facilities and higher budget resources, the most appropriate choice in general is a direct strategy for mutation detection. However, in countries with limited facilities and low budget resources, carrier detection and prenatal diagnosis are usually performed by linkage analysis with genetic markers. This article reviews the genetic diagnosis of haemophilia, genetics and inhibitor development, genetics of von Willebrand's disease and of rare bleeding disorders.
Similar articles
-
Carrier detection and prenatal diagnosis of hemophilia in developing countries.Semin Thromb Hemost. 2005 Nov;31(5):544-54. doi: 10.1055/s-2005-922226. Semin Thromb Hemost. 2005. PMID: 16276463 Review.
-
Rare bleeding disorders.Haemophilia. 2006 Jul;12 Suppl 3:137-42. doi: 10.1111/j.1365-2516.2006.01271.x. Haemophilia. 2006. PMID: 16684009 Review.
-
Hemophilia and von Willebrand's disease: genetic considerations.Ann Clin Lab Sci. 1980 Mar-Apr;10(2):123-7. Ann Clin Lab Sci. 1980. PMID: 6770741 Review.
-
Inherited platelet function disorders versus other inherited bleeding disorders: an Indian overview.Thromb Res. 2008;121(6):835-41. doi: 10.1016/j.thromres.2007.07.015. Epub 2007 Sep 11. Thromb Res. 2008. PMID: 17850851
-
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.East Mediterr Health J. 1999 Nov;5(6):1188-95. East Mediterr Health J. 1999. PMID: 11924110
Cited by
-
Comparison of free-living physical activity measurements between ActiGraph GT3X-BT and Fitbit Charge 3 in young people with haemophilia.Haemophilia. 2022 Nov;28(6):e172-e180. doi: 10.1111/hae.14624. Epub 2022 Jul 13. Haemophilia. 2022. PMID: 35830613 Free PMC article.
-
Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment.Transfus Med Hemother. 2013 Oct;40(5):352-5. doi: 10.1159/000354843. Epub 2013 Aug 26. Transfus Med Hemother. 2013. PMID: 24273489 Free PMC article. Review.
-
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).Pharmacogenomics J. 2024 Mar 4;24(2):6. doi: 10.1038/s41397-024-00328-z. Pharmacogenomics J. 2024. PMID: 38438359 Free PMC article.
-
Clinico-epidemiological and sociodemographic profile of patients with hemophilia in the Brazilian Amazon: High prevalence of hepatitis C infection and its possible corrrelation with inhibitor development.Front Public Health. 2022 Sep 8;10:963790. doi: 10.3389/fpubh.2022.963790. eCollection 2022. Front Public Health. 2022. PMID: 36159250 Free PMC article.
-
Therapeutic Applications of the CRISPR-Cas System.Bioengineering (Basel). 2022 Sep 15;9(9):477. doi: 10.3390/bioengineering9090477. Bioengineering (Basel). 2022. PMID: 36135023 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources